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Mechanism of steroid action in renal epithelial cells. Renal
tubular epithelial cells (TEC) are thought to play an active
role in tubulointerstitial inflammation. Various immune and
non-immune factors activate TEC to produce a variety of cy-
tokines and chemokines, contributing to attraction of inflam-
matory cells to the kidney. The proinflammatory transcription
factor nuclear factor-jB (NF-jB) appears to be a key player
in these responses and tubular expression of NF-jB has been
demonstrated in vitro and in vivo. Although glucocorticoids
are known to inhibit NF-jB activation at different levels, the
proinflammatory capacity of TEC was not inhibited. In contrast,
glucocorticoids seemed to enhance the profibrotic response of
TEC, emphasizing the cell-type specific characteristics of gluco-
corticoid action. We propose that specific inhibition of NF-jB
activation in TEC might be an attractive strategy for therapeutic
intervention in renal inflammation.
Influx of monocytes and T cells into the tubulointer-
stitial area of the kidney is a hallmark of many renal in-
flammatory diseases. Renal tubular epithelial cells (TEC)
are an important source of cytokines and chemokines
and may thereby play an important role in the attrac-
tion of these cells to the kidney [1]. Glucocorticoids are
potent suppressors of the immune system and are there-
fore used as therapeutic treatment in a broad range of
autoimmune and inflammatory diseases. One of the ma-
jor anti-inflammatory actions of glucocorticoids is sup-
pression of cytokine production [2]. Nuclear factor-jB
(NF-jB) is a proinflammatory transcription factor that
regulates the expression of many inflammatory media-
tors [3]. As a key regulator of immune responses, NF-jB
has been suggested to play a pivotal role in a variety of
immune-mediated pathophysiologic conditions, includ-
ing renal disease [4]. Inhibition of cytokine production
by glucocorticoids has been attributed to inhibition of
NF-jB [5, 6].
In recent years, the function of glucocorticoids has
been investigated in a variety of cell types [7–9]. Fur-
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thermore, the interaction between glucocorticoids and
NF-jB has been subject of numerous studies [10–16].
One important lesson to learn from these studies is that
the effect of glucocorticoids is cell type–specific and that
one should be careful to extrapolate data from one cell
type to another. In the present review, we describe the
mechanism of steroid action in renal tubular epithelial
cells. We present an overview of the levels of interaction
between steroids and NF-jB and demonstrate the impor-
tance of this interaction for regulation of cytokine pro-
duction by TEC and the potential implications for renal
inflammation.
TECs AND RENAL INFLAMMATION
Progressive loss of renal function is thought to be the
result of a common pathogenic pathway independent of
the original disease. This progressive chronic renal fail-
ure is associated with interstitial infiltration and tubular
injury [17, 18]. Similar processes are observed in renal al-
lograft rejection, in which tubulointerstitial infiltration of
mainly T cells and monocytes is a prominent feature [19,
20]. Infiltration is critically dependent on the expression
of chemokines [21], which are produced intrarenally [22,
23]. TECs are considered to be a central cell type in renal
inflammation because they are able to produce a large
variety of cytokines [interleukin (IL)-6, tumor necrosis
factor-a (TNF-a)] and chemokines [IL-8/CXCL8, mono-
cyte chemoattractant protein-1 (MCP-1)/CCL2, regu-
lated upon activation, normal T cell expressed and
secreted (RANTES)/CCL5] [1]. These chemokines are
sequestered in the tubular basement membrane, provid-
ing a chemokine concentration gradient that peaks at the
tubuli [20].
Different circumstances might trigger TEC activation,
including ischaemia/hypoxia caused by glomerular injury
or transplantation procedures [18]. Another factor con-
tributing to activation of tubular epithelial cells is ex-
posure to protein overload due to enhanced glomerular
permeability. In vitro exposure of renal epithelial cells to
albumin resulted in increased production of IL-8, MCP-
1, and RANTES [24–26]. IL-8 was predominantly se-
creted at the basolateral site, suggesting accumulation in
the interstitial space [26]. Cross-talk between TECs and
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Fig. 1. Schematic representation of immune
and non-immune factors inducing activation
of tubular epithelial cells (TEC).
infiltrating leukocytes also constitutes an important part
of the regulation of production of inflammatory media-
tors by TEC. In vitro studies have shown that TEC are
strongly activated by TNF-a and IL-1, which are mainly
produced by monocytes. In addition, T-cell–derived fac-
tors like IL-17 and interferon-c (IFN-c) and the cell
surface molecule CD40L strongly induce cytokine and
chemokine production by TEC [27–30].
The increase in chemokine production by TEC might
lead to further attraction of inflammatory cells to the kid-
ney, thereby generating an amplification loop for acti-
vation. The ratio of different chemokines produced will
determine the composition of the infiltrate. Interstitial
cross-talk might also be involved in T-cell proliferation
at the site of inflammation. For instance, activated TEC
have been shown to produce IL-15, a cytokine with T-
cell growth factor activity [31, 32]. A detailed description
of the various cytokines that can be produced by TEC
and their respective receptors and target cells has previ-
ously been presented [33]. Next to chemokines, activated
TEC express increased levels of adhesion molecules and
major histocompatibility complex (MHC) class II, which
can also be involved in the cross-talk with T cells and
monocytes [34].
TECs are not only an important source of cytokines
and chemokines, but are also capable of producing profi-
brotic factors, including transforming growth factor beta
(TGF-b) and platelet-derived growth factor (PDGF) [18,
35, 36]. Furthermore, activated renal epithelial cells are
able to produce endothelin-1 (ET-1), which enhances ma-
trix synthesis by fibroblasts [17]. Moreover, TEC might
contribute directly to the excessive matrix production
by synthesis of extracellular matrix components (colla-
gens, fibronectin, laminin) [18]. Finally, it has been sug-
gested that TEC can transdifferentiate into fibroblasts via
a process called epithelial-mesenchymal transition [35,
37]. Taken together, activated tubular cells play an impor-
tant role in aggravating local inflammation and fibrosis,
ultimately leading to permanent loss of integrity and func-
tion of the kidney. A schematic representation of TEC
activation is shown in Figure 1.
GLUCOCORTICOIDS AND NF-jB
Glucocorticoid action
Glucocorticoids are known to modulate a variety of
cellular processes and play an important role in home-
ostasis and development. Furthermore, glucocorticoids
are potent suppressors of the immune system and are
therefore used as therapeutic treatment in a broad range
of autoimmune and inflammatory diseases. Glucocorti-
coid action is mediated via binding to the glucocorticoid
receptor. The inactive receptor is bound to chaperone
proteins, including two heat shock protein (hsp90) sub-
units and is located in the cytoplasm [38, 39]. Upon
ligand binding, the activated glucocorticoid receptor dis-
sociates from the chaperone complex and translocates to
the nucleus to activate or repress transcription of gluco-
corticoid target genes. Stimulation of gene transcription
is mediated via binding of glucocorticoid receptors to glu-
cocorticoid responsive elements (GREs) in the promoter
region of glucocorticoid-responsive genes [6, 38, 39].
One of the major anti-inflammatory actions of gluco-
corticoids is suppression of cytokine production [2]. Glu-
cocorticoids can inhibit gene transcription via negative
GREs. However, several genes that are negatively regu-
lated by steroids, including cytokine genes, do not contain
a negative response element in their promoter. Expres-
sion of these genes is inhibited via glucocorticoid-induced
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repression of transcription factors, including activating-
protein-1 (AP-1) and NF-jB [40]. Many anti-
inflammatory effects of glucocorticoids have been
linked to their ability to inhibit the activation of NF-jB
[5, 6].
NF-jB activation
The transcription factor NF-jB is a key player of in-
flammatory processes regulating the expression of nu-
merous proteins involved in inflammation [3]. Target
genes include cytokines (IL-6), chemokines (IL-8, MCP-
1, and RANTES), and cell adhesion molecules [inter-
cellular adhesion molecule-1 (ICAM-1) and vascular
adhesion molecule-1 (VCAM-1)] [5, 41]. The classical
form of NF-jB is a heterodimer of a p50 and a p65 subunit
[41, 42]. In the cytoplasm, NF-jB is kept inactive through
binding to its endogenous inhibitor, IjB-a. NF-jB can
be activated by a variety of stimuli, including cytokines
like IL-1 and TNF-a, which induce phosphorylation and
subsequent degradation of IjB-a. The released NF-jB
translocates to the nucleus to activate transcription of
target genes [42, 43].
Considering the important role of NF-jB in the in-
flammatory process it is not surprising that dysregulation
of NF-jB is associated with inflammatory diseases, such
as rheumatoid arthritis, asthma, and inflammatory bowel
disease [5, 41, 44]. Increased tissue expression of NF-jB
can lead to enhanced production of inflammatory medi-
ators and the recruitment of inflammatory cells, which
are characteristic of these chronic inflammatory diseases.
Also in the pathogenesis of allograft rejection a crucial
role for NF-jB was demonstrated [5, 45]. Furthermore,
NF-jB has been implicated in the process of atherosclero-
sis. The observation that NF-jB is also a critical regulator
of cell proliferation and apoptosis has important implica-
tions for the role of NF-jB in the pathogenesis of cancer
[46–48]. The importance of NF-jB in renal disease, as
demonstrated in vivo in experimental models of nephri-
tis and tubulointerstitial disorders, has been previously
reviewed [4].
Inhibition of NF-jB activation by glucocorticoids
The mechanism of NF-jB suppression by glucocorti-
coids has been studied extensively. Initially, it was postu-
lated that steroids inhibit NF-jB activation by increasing
the transcription of IjB-a, the endogenous inhibitor of
NF-jB [10, 11]. The newly synthesized IjB-a could se-
quester NF-jB in the cytoplasm or, alternatively, remove
NF-jB from DNA and transport the NF-jB complexes
to the cytosol via a nuclear export signal in the N-
terminal domain of IjB-a, thereby terminating NF-jB–
dependent transcriptional activation [49, 50]. Subsequent
studies have demonstrated that the activated glucocorti-
coid receptor can bind to the p65 subunit of NF-jB, thus
interfering in the binding of NF-jB to DNA [12, 13].
However, glucocorticoid-mediated suppression of NF-
jB without induction of IjB-a synthesis or inhibition of
DNA binding has been shown in other studies [51–53].
In other studies it has been described that corticosteroids
can interfere with the transactivating potential of NF-
jB without affecting DNA binding, either by competi-
tion for limited amount of cofactors like cyclic adenosine
monophosphate (cAMP)-responsive element binding
protein (CREB) binding protein (CBP) and steroid re-
ceptor coactivator-1 (SRC-1) or by interference with the
mechanistic interaction of p65 with the basal transcrip-
tion machinery [14–16]. Figure 2 gives an overview of the
levels of interaction between steroids and NF-jB.
STEROID RESPONSIVENESS OF RENAL
EPITHELIAL CELLS
Production of inflammatory mediators
Treatment of renal inflammatory diseases usually
includes glucocorticoids. Although glucocorticoids are
known to have a profound effect on cytokine pro-
duction by a variety of cell types [7–9], we have re-
cently shown that production of cytokines (IL-6) and
chemokines (MCP-1 and IL-8) by primary human TEC
that were activated with IL-1, TNF-a, or CD40L was in-
sensitive to the inhibitory action of dexamethasone [54].
In parallel experiments, cytokine and chemokine pro-
duction by human TEC was strongly inhibited by two
NF-jB inhibitors, the antioxidant pyrrolidine dithiocar-
bamate (PDTC) and the proteosome inhibitor n-tosyl-l-
phenylalanine chloromethylketone (TPCK), which act at
the level of IjB phosphorylation and degradation [55, 56].
Similar results were found with another antioxidant, N-
acetylcysteine (NAC), and with the newly described NF-
jB inhibitor caffeic acid phenethyl ester (CAPE) [57],
confirming a role for NF-jB in cytokine production by
human TEC.
Other studies have also addressed the role of NF-jB
in cytokine production by renal epithelial cells in vitro.
Stimulation of human TEC with MCP-1 in the presence
of PDTC resulted in inhibition of IL-6 production and
ICAM-1 expression, which was confirmed by the use of
decoy oligonucleotides [58]. Another study on human
TEC demonstrated a role for NF-jB in albumin-induced
IL-8 production using PDTC and a cell-permeable pep-
tide inhibitor of NF-jB [26]. Other studies have been
performed on cultured TEC of different origin. In rat
TEC, inhibition of NF-jB with TPCK or an antisense
oligonucleotide to the rat p65 subunit of NF-jB inhib-
ited albumin-induced MCP-1 production [24], whereas
in the LLC-PK1 cell line, PDTC inhibited albumin-
induced RANTES production [25]. Using the same cell
line, activation of NF-jB was demonstrated following
simulated ischemia [59]. Furthermore, transfection of
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Fig. 2. Levels of interaction between steroids and nuclear factor-jB (NF-jB). Triggering of cytokine receptors leads to the generation of reactive
oxygen species (ROS), resulting in activation of the IjB kinase (IKK) complex. In turn, this complex phosphorylates the endogenous inhibitor of
NF-jB, IjB-a, which is targeted for proteosome-mediated degradation. The released NF-jB translocates to the nucleus to activate the transcription
of target genes. Glucocorticoids can interfere with the NF-jB pathway at different levels. (1) The activated glucocorticoid receptor (GR) can bind to
glucocorticoid-responsive elements (GRE) in the promoter of the IjB-a gene and induce increased synthesis of IjB-a. NF-jB itself can also bind to
this promoter as part of a negative feedback mechanism to shut-down NF-jB activation. Steroids can also directly interfere in transactivation via (2)
protein-protein interaction to prevent DNA-binding, (3) competition for cofactors, or (4) interference with the activation of the basal transcription
machinery, either via protein-protein interaction or via attraction of a corepressor. Other NF-jB inhibitors act at the level of ROS [pyrrolidine
dithiocarbamate (PDTC) and N-acetylcysteine (NAC)], proteosome inhibition [n-tosyl-l-phenylalanine chloromethyl ketone (TPCK)] and nuclear
translocation [caffeic acid phenethyl ester (CAPE)].
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Fig. 3. Regulated upon activation, normal T cell expressed and se-
creted (RANTES) production by tubular epithelial cells (TEC) is not
inhibited by dexamethasone. Primary human TEC were stimulated for
48 hours with irradiated CD40L-transfected cells or control cells in a
1:1 ratio. RANTES was measured in culture supernatants by specific
enxyme-linked immmunosorbent assay (ELISA). Preincubation for 2
hours with increasing doses of dexamethasone had no effect on CD40L-
induced RANTES production (A), whereas the antioxidant pyrrolidine
dithiocarbamate (PDTC) dose-dependently inhibited RANTES pro-
duction (B).
dominant-negative forms of the IKK subunits in mouse
TEC inhibited transcription of the VCAM-1 promoter in
mouse TEC [60]. In conclusion, NF-jB appears to be a
common mediator in TEC activation. It is likely that NF-
jB activation also plays an important role in other cell
types present in the inflamed kidney, including mesangial
cells, fibroblasts, endothelial cells, and infiltrating leuko-
cytes, but a detailed description is beyond the scope of
this review.
In contrast to TEC, dexamethasone strongly inhibited
cytokine production in renal fibroblasts and lung epithe-
lial cells, emphasizing the cell-type specificity of glucocor-
ticoid action. Our data are in line with previous studies,
showing that IL-15 production by TEC was not inhibited
by dexamethasone [32] or that dexamethasone was un-
able to inhibit ICAM-1 expression on TEC [61]. In con-
trast to these findings, dexamethasone has been shown
to partially inhibit MCP-1 production in rat TEC [24] or
RANTES production by distal and proximal human TEC
stimulated with a combination of IL-1b , TNF-a, and IFN-
c [62]. Both the origin of the epithelial cell or the nature
of the stimulus (protein overload or IFN-c) might con-
tribute to this discrepancy. Using CD40L as a stimulus,
we found that RANTES production by human proxi-
mal TEC was not inhibited by dexamethasone (Fig. 3A),
whereas PDTC dose-dependently inhibited RANTES
production (Fig. 3B). As observed for primary cells,
dexamethasone was unable to inhibit cytokine produc-
tion by the TEC-derived cell-line HK-2, which provides
a helpful tool to enable detailed biochemical analysis of
the mechanism underlying the steroid insensitivity of re-
nal epithelial cells.
Suppression of NF-jB activity
NF-jB pathway. The observed lack of inhibition by
glucocorticoids suggests that in renal TEC the NF-jB sig-
naling pathway is insensitive to glucocorticoids. We have
shown that dexamethasone is unable to increase IjB-a
synthesis or block DNA-binding activity in response to
IL-1 [63]. The lack of IjB-a induction was interesting,
since stimulation of gene expression by dexamethasone
was still intact in these cells (see below). This observa-
tion is not specific for TEC, as in A549 cells, dexametha-
sone increased the expression of the b 2-adrenoreceptor
without an effect on IjB-a expression [64]. Furthermore,
in L929 cells various glucocorticoids, including dexam-
ethasone, failed to increase IjB-a expression while all
of them induced activation of the mouse mammary tu-
mor virus (MMTV) promoter, which contains several
GREs [65]. Although the IjB-a promoter contains sev-
eral partial GREs, it does not contain a full GRE, which
may account for the differential induction of this gene
[66]. In addition, it has been shown that the IjB-a and
MMTV promoter have a different chromatin organiza-
tion. Therefore, glucocorticoid activation of each pro-
moter may require different coactivator complexes [67].
Lack of IjB-a induction by dexamethasone was observed
in many other cell-types [8, 51, 52, 68–70], indicating that
this mechanism of NF-jB repression is not a universal
mechanism and seems to be highly tissue- or cell-specific.
Reporter assays demonstrated a clear discrimination in
steroid responsiveness between renal and lung epithelial
cells, which was associated with a failure of dexametha-
sone to inhibit the transactivation capacity of NF-jB in
HK-2 [63]. Glucocorticoid-insensitive NF-jB activation
has also been shown in other cell systems [7, 69, 70]. How-
ever, in these studies expression of adhesion molecules
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and cytokines was reduced by dexamethasone, while in
activated human TEC, all inflammatory mediators we
have studied so far, including IL-6, RANTES, MCP-1,
IL-8, and ICAM-1, seem to be insensitive to dexametha-
sone.
In addition to the p50-p65 pathway of NF-jB acti-
vation, alternative pathways have been described [42],
which are regulated via different IjB family members
(IjB-b , IjB-ε, IjB-c, p105, p100, Bcl-3) and lead to the
activation of different NF-jB complexes (p50-p50 ho-
modimers) or different subunits (c-rel, relB, p52). Al-
though the functional role of these alternative pathways
of NF-jB activation is not fully understood, they might
play a role in dexamethasone-insensitive activation of
NF-jB. In view of this, IjB-b has been suggested to play
a role in persistent activation of NF-jB. Like IjB-a, IjB-
b binds to p50-65 and is degraded upon cell activation.
However, synthesis of IjB-b is unaffected by glucocor-
ticoids. Furthermore, newly synthesized IjB-b is unable
to remove NF-jB from DNA and blocks the interaction
with IjB-a, resulting in persistent activation of NF-jB
[71, 72]. As new pathways of NF-jB activation are still
being identified, these might also be important for NF-jB
activation in renal epithelial cells. One important alterna-
tive pathway that has emerged recently is the RelB/p52
pathway, which can be activated by CD40L and has an
important function in lymphoid organ development [73,
74].
As glucocorticoid-mediated inhibition of NF-jB de-
pends on interaction with the p65 subunit, we hypothe-
sized that the lack of repression by glucocorticoids might
be explained by the use of alternative NF-jB pathways in
TEC activation, not involving p65. We focused on the ac-
tivation of p50-p50 homodimers, which are generated via
signal-induced proteolysis of p105, the precursor protein
of p50 [75]. Initially p50-p50 homodimers were thought
to inhibit the activity of the p50-p65 complex [76]. How-
ever, other studies show that these complexes can also
activate transcription of target genes via interaction with
Bcl-3 [77, 78], a unique member of the IjB family which
is most abundant in the nucleus and is not degraded upon
activation of NF-jB. Three observations suggest that the
Bcl-3/p50 pathway might be operational in TEC. First, in
electrophoretic mobility shift assays, we found high lev-
els of p50-p50 homodimers, which were further increased
upon stimulation with IL-1 or CD40L [28, 54]. Second,
we detected high levels of Bcl-3 in nuclear extracts of
TEC (unpublished observations). Third, transcription of
an NF-jB reporter gene was approximately 50% dimin-
ished upon cotransfection with a degradation-resistant
p105, suggesting that at least part of the NF-jB transac-
tivating capacity in TEC is due to the Bcl-3/p50 pathway
(unpublished observations). As this pathway occurs in-
dependently of IjB-a or p65, the Bcl-3/p50 pathway may
represent a dexamethasone-independent way of NF-jB
activation. However, the significance of this pathway for
cytokine production by TEC remains to be determined.
Glucocorticoid pathway. The lack of inhibition by
dexamethasone could potentially also be explained by
aberrant glucocorticoid receptor signaling. Careful ex-
amination of the culture medium for TEC revealed that
hydrocortisone (36 ng/mL) is required to facilitate out-
growth of TECs [79], indicating a special function for
steroids in this cell type. We confirmed that the lack of
dexamethasone-mediated inhibition of cytokine produc-
tion was not due to desensitization by culturing TEC in
hydrocortisone-free medium after initial outgrowth (un-
published observations). Furthermore, we have shown
that glucocorticoid receptor mRNA and protein were ex-
pressed in renal epithelial cells and that expression levels
were comparable to steroid-sensitive cells [54]. We also
excluded that lack of inhibition by dexamethasone was
caused by overexpression of the glucocorticoid receptor
b isoform that could competitively inhibit the functional
glucocorticoid receptor a as was suggested in other stud-
ies [80, 81]. In addition, dexamethasone induced translo-
cation of glucocorticoid receptor from the cytosol to the
nucleus, suggesting that the first part of the signaling
pathway is intact. Finally, we demonstrated that dexam-
ethasone was able to increase transcription of a GRE-
reporter gene as well as two glucocorticoid-target genes,
b 2-adrenoreceptors and angiotensinogen [63].
The latter observation might have important implica-
tions for the progression of renal disease. Proximal TEC
have been shown to express all components of the renin-
angiotensin system (RAS) that are necessary for synthe-
sis and secretion of angiotensin II [82, 83]. The increase
in angiotensinogen expression in response to dexametha-
sone as observed by us and others [83] might lead to in-
creased local production of angiotensin II, which has been
suggested to contribute to the development of fibrosis [84,
85]. In a mouse model of obstructive nephropathy, trans-
genic mice expressing increased levels of angiotensinogen
showed increased renal interstitial fibrosis [86]. Another
important regulator of angiotensinogen expression is NF-
jB itself [36] and part of the anti-inflammatory effects
of angiotensin-converting enzyme (ACE) inhibitors have
been attributed to inhibition of NF-jB [87]. The poten-
tiating effect of dexamethasone on angiotensinogen ex-
pression in combination with a lack of NF-jB inhibition
might provide an amplification loop that up-regulates
angiotensin II production and progression of fibrosis.
Next to angiotensinogen, dexamethasone also has been
shown to increase the production of fibronectin by TEC,
which might also contribute to the fibrotic process [88]. A
schematic representation of the effect of glucocorticoids
on TEC is shown in Figure 4.
Altogether, the steroid insensitivity of renal epithelial
cells appears to be specific for the inhibitory function
of glucocorticoids, whereas the stimulatory function is
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Fig. 4. Steroids and tubular epithelial cells (TEC) in renal inflamma-
tion. Production of cytokines and chemokines by tubular epithelial cells
is insensitive to treatment with dexamethasone, due to a lack of nuclear
factor-jB (NF-jB) inhibition. This might allow for an ongoing immune
response ultimately leading to chronic inflammation and fibrosis. At the
same time, the potentiating effect of dexamethasone on angiotensino-
gen production might provide an amplification loop that up-regulates
angiotensin II (Ang II) production and contributes to progression of
fibrosis.
intact. However, it should be realized that the functional
behavior of TEC in vivo might be affected by their con-
tact with neighboring cells or proteins of the tubular base-
ment membrane. Therefore, further research is required
to determine the functional consequenses of NF-jB acti-
vation in renal TEC, either by performing molecular and
biochemical experiments in in vitro co-culture systems
or by directly analyzing NF-jB activation in vivo. New
techniques have become available that allow specific de-
tection of activated NF-jB in tissue sections, which might
be useful for this purpose. Furthermore, the recent devel-
opments in generation of inducible tissue-specific knock-
out mice suggest that this may be a powerful approach
[89]. In addition, it is important to examine the effects of
steroids on renal epithelial cell activation in an experi-
mental model for tubulointerstitial inflammation. A first
step in this approach is to determine whether the steroid
response of human TEC can be extrapolated to other
species.
THERAPEUTIC STRATEGIES
Although glucocorticoids may effectively inhibit T-
cell–mediated immune responses, our data suggest that
the effect of steroids on TEC might be limited. The in-
ability of glucocorticoids to down-modulate the active
state of TEC may lead to continuous NF-jB activation
in this cell type. Increased NF-jB activation in TEC has
been demonstrated in kidney biopsies from patients with
crescentic glomerulonephritis [90], proteinuria [91], dia-
betic nephropathy [92], and in a rat model for proteinuria
[93], emphasizing the importance of tubular cell activa-
tion for renal disease. In the presence of glucocorticoids,
activated TEC may continuously produce inflammatory
mediators, which might allow for an ongoing low-grade
immune response ultimately leading to the development
of chronic inflammation and fibrosis. In addition, we have
demonstrated that steroids stimulate the production of
profibrotic factors by TEC. This is particularly relevant
for renal transplantation, where acute and chronic rejec-
tion develop despite the use of glucocorticoids as main-
tenance therapy. Nonimmune factors, including protein
overload, may further contribute to the continuous acti-
vation of NF-jB in TEC. Therefore, novel immunosup-
pressive strategies need to be developed to inhibit the
proinflammatory capacity of TEC.
Inhibition of NF-jB activation is a potential therapeu-
tic strategy for treatment of chronic inflammation and
cancer [5, 94]. The importance of NF-jB in renal dis-
ease also makes this transcription factor an attractive
target for therapeutic intervention in renal inflamma-
tion. In addition to glucocorticoids, other well-known NF-
jB inhibitors are nonsteroidal anti-inflammatory drugs
(NSAIDs) like aspirin and sodium salicylate. Further-
more, proteasome inhibitors and antioxidants are known
to inhibit NF-jB activation by preventing the phospho-
rylation and degradation of IjB-proteins [5, 94]. In var-
ious in vivo models of renal tubular damage, inhibition
of NF-jB by administration of antioxidants (PDTC and
NAC) has been shown to have beneficial effects on tubu-
lointerstitial injury [95, 96]. One concern is the specificity
of the drugs. For example, inhibition of proteasome ac-
tivity could potentially cause severe side-effects due to
inhibition of other important functions apart from IjB
degradation or inhibition of other cell types than renal
TEC. Also prolonged inhibition of NF-jB might not be
feasible concerning the role for NF-jB in host defense.
Therefore, site-specific suppression of NF-jB pathway
may be required for therapeutic applications.
In a rat model for tubulointerstitial injury, injection
of adenovirus in the renal artery resulted in selective
gene transfer into proximal tubular cells [97, 98]. Us-
ing this method, tubular expression of truncated IjB-a,
which lacks the phosphorylation sites essential for NF-
jB activation, resulted in attenuation of tubulointersti-
tial injury, including decreased interstitial infiltration of
mononuclear cells and reduced interstitial fibrosis. Pos-
sible strategies for gene transfer into the kidney have
recently been reviewed [99]. Importantly, these results
demonstrate that specific targeting of TECs can be a use-
ful tool in the treatment of renal disease.
Inhibition of NF-jB might also have beneficial effects
in renal allograft rejection. Although immunosuppres-
sive agents currently in clinical use are very effective
in the short term, this has not resulted in a correspond-
ing increase in long-term graft survival, suggesting that
the available agents do not effectively control the im-
mune system and are unable to prevent chronic rejec-
tion [100]. Furthermore, these agents act on the immune
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Fig. 5. Effect of immunosuppressive agents
on interleukin (IL)-6 production by tubu-
lar epithelial cells (TEC). Primary human
TEC were incubated for 2 hours with
100 nmol/L cyclosporin (CsA), tacrolimus
(FK506), sirolimus/rapamycin (Rapa), my-
cophenolic acid (MPA), and prednisolone
(Pred) for 2 hours prior to stimulation with
CD40L-transfected cells for 48 hours. Pyrro-
lidine dithiocarbamate (PDTC) (15 lmol/L)
was used as positive control. IL-6 produc-
tion in culture supernatants was measured
by specific enzyme-linked immunosorbent as-
say (ELISA). No effect was observed with
vehicle-treated cells.
system non-specifically, putting patients at risk for infec-
tion and cancer. Immunosuppressants such as cyclosporin
and tacrolimus have been shown to inhibit NF-jB activa-
tion [5, 94]. Of note, we have studied the effect of differ-
ent immunosuppressive agents on cytokine production
by TEC in vitro and observed no inhibition with cy-
closporin, tacrolimus, sirolimus, mycophenolic acid, and
prednisolone (Fig. 5), strengthening the idea of using
specific NF-jB inhibition for therapeutic use. Two stud-
ies have used this approach in a rat renal allograft
model. Transfection of NF-jB-decoy oligonucleotides
into donor kidney prior to transplantation resulted in in-
creased survival and renal function associated with de-
creased expression of NF-jB–regulated cytokines and
adhesion molecules [101]. Using a similar setup, a reduc-
tion in monocyte infiltration was observed [102].
In order to find new strategies to inhibit the proin-
flammatory capacity of TEC it is important to identify
additional signaling pathways involved in the produc-
tion of inflammatory mediators by TEC. In addition to
NF-jB, mitogen-activated protein kinases (MAPK) have
been implicated in the regulation of cytokine gene expres-
sion [103–105]. In mammalian cells, three major groups
of MAPK have been described: extracellular signal-
regulated protein kinase (ERK), p38 MAPK, and c-Jun
NH2-terminal kinase (JNK). Recently we have shown
that blockade of JNK, but not ERK or p38, strongly
inhibited IL-1–induced IL-6 production by TEC. Inter-
estingly, the regulation of IL-6 production by JNK was
dependent on interaction of c-jun, the effector pro-
tein of the JNK pathway and part of the AP-1 tran-
scription factor complex, with NF-jB (manuscript in
preparation). From a therapeutic point of view, this ob-
servation implicates that inhibition of JNK might induce
a selective down-regulation of NF-jB in response to an
inflammatory stimulus, possibly leaving innate responses
intact. Further investigation is required to determine
the cell type and stimulus specificity of the JNK-NF-jB
interaction.
To further identify possible targets in the NF-jB
pathway we determined the gene expression profile of
96 genes related to NF-jB–mediated signal transduc-
tion using a cDNA expression array (Fig. 6A). One of
the genes that was highly expressed appeared to be
TRAF1, a member of the TNF receptor-associated factor
(TRAF) family. Abundant expression was also found us-
ing Affymetrix Focus Arrays and was confirmed with re-
verse transcription-polymerase chain reaction (RT-PCR)
(Fig. 6B). TRAFs are considered to play a central role in
transducing signals from the TNF-R as well as the IL-
1-R superfamily and are suggested to be the bifurcation
point of NF-jB and JNK signaling pathways [106, 107].
TRAF1 is unique among the TRAF molecules since it
contains no RING finger motif. In accordance with our
observations, NF-jB inducing receptors, including IL-1-
R and CD40, have been shown to increase TRAF1 ex-
pression [108]. Although the physiologic role of TRAF1
is largely unknown, TRAF1 has been suggested to mod-
ulate sustained activation of NF-jB and JNK [109]. Ad-
ditional research is required to examine whether newly
identified factors like JNK and TRAF1 might serve as po-
tential targets for therapeutic intervention. Furthermore,
microarray analysis of cultured human TEC might lead
to the identification of tubular specific expression pat-
terns in response to inflammatory stimuli, which might
be associated with progression of renal disease.
Although many studies point toward NF-jB as a
central mediator of cytokine gene expression, other
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Fig. 6. Gene expression analysis of nuclear factor-jB (NF-jB)-related
genes in control tubular epithelial cells (TEC). (A) To determine the
gene expression profile of TEC, total RNA was isolated from con-
trol TEC following the Qiagen RNeasy purification protocol (Qiagen,
Hilden, Germany). Biotinylated cDNA was hybridized to a GEArray
containing 96 genes of the human NF-jB signaling pathway accord-
ing to manufacturer’s instructions (Superarray, Bethesda, MD, USA).
Abundant expression of tumor necrosis factor-receptor associated fac-
tor (TRAF1) was observed in four of four independent TEC samples.
(B) Semiquantitative reverse transcription-polymerase chain reaction
(RT-PCR) was performed as previously described [114]. M is marker,
10 to 1000, dilutions of cDNA. Expression of TRAF1 could be detected
up to a cDNA dilution of 1/1000.
transcription factors may also be involved, which may
also serve as therapeutic targets. For instance, studies
on the regulation of IL-6 gene expression have demon-
strated the functional involvement of binding sites for
NF-jB, AP-1, CREB and CCAAT enhancer-binding pro-
tein (C/EBPb or NF-IL6) in the IL-6 promoter [110–113].
A better understanding of the role of each of these tran-
scription factors in cytokine production and their impor-
tance for the pathogenesis of renal disease may provide
the means to determine which factor will ultimately be
the most attractive target for inhibition.
CONCLUSION
Renal TEC are considered to play an active role in
the amplification of tubulointerstitial infiltration and the
progression to fibrosis and renal failure. The transcription
factor NF-jB appears to play a central role in the acti-
vation of TEC. Although glucocorticoids are known to
inhibit the NF-jB pathway at different levels, the proin-
flammatory capacity of TEC was not inhibited, which was
due to a specific lack of NF-jB inhibition in this cell-type.
Since NF-jB seems to be the master switch in a vari-
ety of processes, including ischemia, protein overload,
graft rejection, and fibrosis, specific NF-jB inhibitors
might be considered for additional treatment of renal
inflammation.
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